Midvastus Versus Medial Parapatellar Approach for Minimally Invasive Total Knee Arthroplasty
Launched by HEEKIN ORTHOPEDIC RESEARCH INSTITUTE · May 27, 2010
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient is a male or non-pregnant female between the ages of 21-80.
- • 2. Patient requires cemented primary total knee replacement.
- • 3. Patient has a diagnosis of osteoarthritis (OA), traumatic arthritis (TA) or avascular necrosis (AVN).
- • 4. Patient has intact collateral ligaments.
- • 5. Patient has signed and dated an IRB approved study specific consent form.
- • 6. Patient is able and willing to participate in the study according to the protocol for the full length of the expected term of follow-up, and to follow their physician's directions.
- • 7. Patient has failed to respond to conservative treatment modalities.
- Exclusion Criteria:
- • 1. Patient has had a prior procedure of high tibial osteotomy, cruciate ligament reconstruction or patellectomy of the surgical knee.
- • 2. Patient is morbidly obese, \>60% over ideal body weight for frame and height.
- • 3. Patient has a deformity at the involved knee greater than 45 degrees of flexion, 45 degrees of varus or 45 degrees of valgus.
- • 4. Patient has an active or suspected latent infection in or about the knee joint.
- • 5. Patient has a malignancy in the area of the involved knee joint.
- • 6. Patient has a diagnosed systemic disease that would affect the subject's welfare or overall outcome of the study (i.e. moderate to severe osteoporosis, Paget's disease) or is immunologically suppressed, or receiving steroids in excess of physiologic dose requirements.
- • 7. Patient has a neurological deficit, which interferes with the patient's ability to limit weight bearing or places an extreme load on the implant during the healing period.
- • 8. Female patient is or plans to become pregnant during the course of the study.
- • 9. Patient has a known sensitivity to device materials.
- • 10. Patient has prior diagnosis of diabetic or peripheral neuropathy in operative extremity or other neurologic disease affecting limb strength
- • 11. Patient's bone stock is compromised by disease or infection, which cannot provide adequate support and/or fixation to the prosthesis.
About Heekin Orthopedic Research Institute
The Heekin Orthopedic Research Institute is a leading organization dedicated to advancing orthopedic research and improving patient outcomes through innovative clinical trials. With a focus on developing and evaluating cutting-edge treatments and surgical techniques, the institute collaborates with orthopedic specialists, healthcare professionals, and academic institutions to foster a comprehensive understanding of musculoskeletal conditions. By prioritizing rigorous scientific methodologies and ethical standards, the Heekin Orthopedic Research Institute aims to contribute significantly to the field of orthopedics, enhancing both clinical practice and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jacksonville, Florida, United States
Patients applied
Trial Officials
R. David Heekin, M.D.
Principal Investigator
Heekin Institute for Orthopedic Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials